Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2221 to 2235 of 8936 results

  1. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  5. Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  7. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  9. Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]

    Awaiting development Reference number: GID-TA11933 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment

    In development Reference number: GID-HTE10065 Expected publication date:  02 April 2026

    Health technology evaluations
    In development

  12. ID6611 Obesity, overweight - semaglutide (including review of TA875)

    Awaiting development Reference number: GID-TA11851 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  14. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development